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Factor Xa represents an attractive target for antithrombotic 
drugs as blockade of factor Xa permits inhibition of both the 
extrinsic and intrinsic coagulation pathways. Several factor 
Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, 
have been approved for certain conditions, and are also in 
clinical development for other indications.
3.1  Rivaroxaban
Rivaroxaban (Fig. 3.1) is a novel factor Xa inhibitor that 
exhibits predictable pharmacokinetics, with high oral bio-
availability, rapid onset of action (achieves maximum plasma 
concentration in 1.5–2.0 h), and no known food interactions 
[1] (see Table 2.1). The drug has a dual mode of elimination: 
two-thirds of it is metabolized by the liver (mostly via 
CYP3A4 and CYP2J2), with no major or active circulating 
metabolites identified, and one-third is excreted unchanged 
by the kidneys. Elimination of rivaroxaban from plasma 
occurs with a terminal half-life of 5–9 h in young individuals, 
and with a terminal half-life of 12–13 h in subjects aged 
>75 years [2]. Available data indicate that body weight, age, 




pharmacokinetics and pharmacodynamics of rivaroxaban, 
and it thus can be administered in fixed doses without coagu-
lation monitoring. Rivaroxaban has minimal drug interac-
tions (eg, with naproxen, acetylsalicylic acid, clopidogrel, or 
digoxin) [1] and its predictable pharmacokinetics and phar-
macodynamics allow use of rivaroxaban without regular lab-
oratory monitoring. Although no specific antidote is known 
for rivaroxaban, preclinical data suggested that recombinant 
factor VIIa and activated prothrombin complex concentrate 
may reverse the effects of high-dose rivaroxaban [3–5]. The 
clinical development programs for rivaroxaban are outlined 
in Table 3.1 [6–23].
3.1.1  Venous Thromboembolism Prevention 
following Joint Surgery
Four completed phase II efficacy and safety studies of rivar-
oxaban for the prevention of VTE in patients undergoing 
elective THR and TKR (n = 2907 patients) have demon-
strated comparable efficacy and safety of rivaroxaban and 
conventional management with subcutaneous enoxaparin 
[6–9, 24]. Efficacy was assessed as a composite of any DVT 
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Table 3.1 Clinical development program from rivaroxaban





ODIXa-HIP [6] Enoxaparin (722)
ODIXa-KNEE [7] Enoxaparin (621)
ODIXa-OD-HIP [8] Enoxaparin (873)
Phase III
RECORD1 [9] Enoxaparin (3153)
RECORD2 [10] Enoxaparin + placebo 
(2509)
RECORD3 [11] Enoxaparin (2556)
RECORD4 [12] Enoxaparin (3148)
VTE prevention Phase II



















ROCKET-AF [18] Warfarin (14,264)




 pulmonary embolism (PE) and  all- cause mortality; safety was 
judged on the basis of major hemorrhage incidence. A pooled 
analysis of two of these studies confirmed non-inferiority of 
rivaroxaban in patients undergoing elective THR or TKR, 
with no significant dose- response relationship for efficacy but 
with a significant dose- related increase for the primary safety 
endpoint (P < 0.001), a total daily dose of 5–20 mg being the 
optimal dose range (Fig. 3.2) [9, 25].
Consequently, a fixed dose of rivaroxaban 10 mg qd was 
selected to be used in the phase III RECORD (REgulation 
of Coagulation in ORthopedic surgery to prevent DVT and 
PE) program (Table 3.2) [9–12]. The RECORD program 
included four large trials that recruited more than 12,500 
patients undergoing elective THR or TKR. All RECORD 
trials have the composite primary efficacy endpoint of DVT, 
nonfatal PE, or all-cause mortality, and the main secondary 
efficacy endpoint was major VTE. The primary safety 
Table 3.1 (continued)



















AF atrial fibrillation, LMWH low-molecular-weight heparin, VKA 
vitamin K antagonist, VTE venous thromboembolism
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 endpoint was major hemorrhage. These studies had no upper 
age limit and allowed recruitment of patients with mild or 
moderate hepatic impairment.
The RECORD1 and the RECORD3 studies compared 
rivaroxaban 10 mg qd (starting 6–8 h after surgery) with 
enoxaparin 40 mg qd (starting the evening before surgery) 
both given for 31–39 days (extended prophylaxis) after 
THR (RECORD1) [9] or for 10–14 days (short-term pro-
phylaxis) after TKR (RECORD3) [11]. In both studies 
treatment with rivaroxaban was significantly superior to 
enoxaparin for VTE prevention (Table 3.2). Recognizing 
that current guidelines recommend extended prophylaxis 
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Figure 3.2 Dose-response relationships between rivaroxaban and 
primary efficacy and safety endpoint. Results for the prevention of 
venous thromboembolism after major orthopedic surgery. DVT 
deep vein thrombosis, PE pulmonary embolism (Reproduced with 
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for patients undergoing THR, although this is not done in 
many countries, the RECORD2 trial investigated the 
 efficacy and safety of extended thromboprophylaxis with 
rivaroxaban (5 weeks) compared with short-term  enoxaparin 
40 mg qd for 10–14 days [10]. The study demonstrated that 
prolonged prophylaxis with rivaroxaban was associated 
with reduced incidence of VTE, including symptomatic 
events, after THR. Of note, despite administration of rivar-
oxaban for 3 weeks longer than enoxaparin, the rate of 
major hemorrhage at 5 weeks was low and similar in both 
groups.
In the RECORD4 trial rivaroxaban 10 mg was signifi-
cantly more effective than the North American regimen of 
enoxaparin 30 mg bid (10–14 days) for the prevention of VTE 
in patients undergoing TKR, with similar rates of major hem-
orrhage for both treatments and no serious liver toxicity with 
rivaroxaban [12]. Thus, the superiority of rivaroxaban over 
enoxaparin for VTE prevention was demonstrated in all four 
studies, with a good safety profile. As a result, in 2008 rivar-
oxaban received approval in the European Union (EU) and 
in Canada for the prevention of VTE in patients undergoing 
elective THR or TKR surgery. In July 2011, the FDA 
approved rivaroxaban for prophylaxis of DVT in adults 
undergoing hip and knee replacement surgery.
The utility of rivaroxaban (10 mg qd for up to 5 weeks) for 
VTE prevention in hospitalized medically ill patients was 
assessed in the phase III MAGELLAN study, with short- 
term enoxaparin (10 days followed by placebo) as the com-
parator [22]. At day 10, the primary efficacy outcome 
(composite asymptomatic proximal DVT, symptomatic DVT, 
symptomatic non-fatal PE and VTE-related death) occurred 
in 2.7 % of patients in both treatment groups, demonstrating 
the non-inferiority of rivaroxaban (P = 0.003). At study end 
(day 35) fewer patients treated with rivaroxaban had the pri-
mary outcome (4.4 % vs 5.7 %; P = 0.02 for superiority). 
However, there was an increase in the risk of clinically rele-
vant bleeding in the rivaroxaban group (4.1 % vs 1.7 %; 
P < 0.0001) [23].
3.1 Rivaroxaban
32
3.1.2  Treatment of Venous Thromboembolism
The initial phase IIb ODIXa-DVT [13] and EINSTEIN-DVT 
[14] studies (Table 3.3) assessed the clinical efficacy and safety 
of rivaroxaban for the treatment of VTE in patients with 
acute, symptomatic, proximal DVT without symptomatic 
PE. The treatment was administered for 3 months, with open-
label standard therapy (low-molecular-weight heparin/hepa-
rin following vitamin K antagonist [VKA]) as comparator.
In the ODIXa-DVT study, rivaroxaban doses 10, 20, or 
30 mg bid, or 40 mg qd, were tested [13]. The primary efficacy 
endpoint of reduced thrombus burden on day 21 (assessed by 
quantitative compression ultrasonography) without recur-
rent VTE or VTE-related death was reported in 43.8–59.2 % 
of patients receiving rivaroxaban and in 45.9 % of patients 
receiving standard therapy. The incidence of the primary 
safety endpoint (major hemorrhage) was 1.7–3.3 % in the 
rivaroxaban groups; there were no events in the standard 
therapy group.
In the EINSTEIN-DVT study [14], therapy with rivaroxa-
ban 20–40 mg qd was associated with an incidence of 5.4–
6.6 % for the primary endpoint (the composite of symptomatic, 
recurrent VTE, and deterioration of thrombotic burden, as 
assessed by compression ultrasound and perfusion lung scan) 
compared with 9.9 % in the standard therapy group. The pri-
mary safety endpoint (any clinically relevant hemorrhage) 
developed in 2.9–7.5 % of patients receiving rivaroxaban and 
8.8 % of those on the standard therapy, with no evidence of 
compromised liver function in those receiving rivaroxaban.
Of note, the phase II studies revealed that the twice-daily 
rivaroxaban regimen was more effective for thrombus regres-
sion at 3 weeks, whereas the once- and twice-daily regimens 
showed similar effectiveness at 3-month follow-up [13]. 
Accordingly, an initial intensified twice-daily regimen (rivar-
oxaban 15 mg bid for 3 weeks) followed by long-term 20 mg 
qd dosing was chosen for investigation in the phase III 
EINSTEIN studies: EINSTEIN-DVT, EINSTEIN-PE, and 
EINSTEIN- EXTENSION [15–17].
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Table 3.3 Clinical efficacy and safety of rivaroxaban for the treat-
ment of venous thromboembolism
EINSTEIN-DVT study
Rivaroxaban 






36/1731 (2.1) 51/1718 (3.0)
First major bleeding or 
clinically relevant non- 
major bleeding, n/N (%)
139/1718 (8.1) 138/1711 (8.1)
EINSTEIN-PE study
Rivaroxaban 






50/2419 (2.1) 44/2413 (1.8)
First major or clinically 
relevant non-major 
bleeding, n/N (%)
249/2412 (10.3) 274/2405 (11.4)
EINSTEIN-Ext study
Rivaroxaban 





(composite of DVT or 
non-fatal or fatal PE), 
n/N (%)
8/602 (1.3) 42/594 (7.1)
First major bleeding or 
clinically relevant non- major 
bleeding, n/N (%)
36/602 (6.0) 7/594 (1.2)
Data from [15–17]
DVT deep vein thrombosis, LMWH low-molecular-weight heparin, 




EINSTEIN-DVT was an open-label, randomized, event- 
driven, non-inferiority study that compared oral rivaroxaban 
(15 mg bid for 3 weeks, followed by 20 mg qd) against subcu-
taneous enoxaparin followed by a VKA for 3, 6, or 12 months 
in patients with acute, symptomatic DVT [14]. In parallel, 
EINSTEIN-EXTENSION was a double-blind, randomized, 
event-driven superiority study that compared rivaroxaban 
alone (20 mg qd) with placebo for an additional 6 or 12 
months in patients who had completed 6–12 months of treat-
ment for VTE [15, 17]. The primary efficacy outcome for both 
studies was recurrent VTE. The principal safety outcome for 
EINSTEIN-DVT was major bleeding or clinically-relevant 
non-major (CRNM) bleeding in the initial-treatment study 
and major bleeding in the continued-treatment study. The 
study recruited 3449 patients: 1731 in the rivaroxaban arm 
and 1718 in the conventional management arm [15]. 
Rivaroxaban was non-inferior with respect to the primary 
efficacy outcome while the principal safety outcome occurred 
in 8.1 % of the patients in each group (Table 3.3). In the 
extended-treatment study, which included 602 patients in the 
rivaroxaban group and 594 in the placebo group, rivaroxaban 
had superior efficacy. Four patients in the rivaroxaban group 
had nonfatal major bleeding (0.7 %), versus none in the pla-
cebo group (P = 0.11) (Table 3.3) [15].
In the randomized, open-label, event-driven, non- inferiority 
EINSTEIN-PE trial, 4832 subjects with acute symptomatic 
PE with or without DVT were assigned to either rivaroxaban 
(15 mg bid for 3 weeks, followed by 20 mg qd) or to standard 
therapy with enoxaparin followed by dose- adjusted VKA for 
3, 6, or 12 months [16]. The trial demonstrated that rivaroxa-
ban was non-inferior to standard therapy for the primary 
efficacy outcome symptomatic recurrent VTE (2.1 % versus 
1.8 %, respectively, P = 0.003 for non- inferiority margin) 
(Table 3.3). Also, 10.3 % of patients treated with rivaroxaban 
developed the principal safety outcome of major or CRNM 
bleeding versus 11.4 % in those on standard care (P = 0.23), 
thus suggesting that fixed-dose rivaroxaban can be an effec-
tive and safe therapeutic option in PE.
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In December 2011 rivaroxaban received approval by the 
European Commission for treatment of DVT and prevention 
of recurrent DVT and PE following an acute DVT in adults. 
Additionally, in November 2012 rivaroxaban was approved 
by the FDA for DVT, PE and prevention of recurrent DVT 
and PE following initial treatment.
3.1.3  Stroke Prevention in Atrial Fibrillation
In terms of numbers of patients, stroke prevention in AF is 
potentially the largest indication that may benefit from the 
NOACs. The rising incidence of AF in a progressively 
aging population suggests that millions of people may 
eventually require life-long anticoagulant therapy to pre-
vent severely disabling complications. The ROCKET AF 
study investigated the effectiveness and safety of rivaroxa-
ban 20 mg qd (15 mg qd in those with moderate kidney 
impairment) versus warfarin for the prevention of stroke 
or systemic embolism in 14,264 patients with non-valvular 
AF (NVAF) who were at an increased risk for stroke [18]. 
Rivaroxaban was non-inferior to warfarin for the preven-
tion of stroke or systemic embolism (hazard ratio [HR] in 
the rivaroxaban group, 0.79; 95 % CI, 0.66–0.96; P < 0.001 
for non-inferiority). Moreover, there was no significant 
between-group difference in the risk of major bleeding, 
although intracranial and fatal bleeding occurred less fre-
quently in the rivaroxaban group [18]. In the J-ROCKET 
AF study conducted in Japan, a lower dose of rivaroxaban 
(15 mg qd; 5 mg qd for patients with moderate renal 
impairment) was shown to be non-inferior to warfarin for 
the prevention of stroke or systemic embolism [19].
In November 2011, in view of the results of the ROCKET 
AF study, rivaroxaban was approved by the FDA for the pre-
vention of stroke and systemic embolism in patients with 
NVAF, at a dose of 20 mg (or 15 mg if creatinine clearance 
15–50 ml/min) qd. In December 2011, rivaroxaban was 
approved by the European Commission for prevention of 
3.1 Rivaroxaban
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stroke and systemic embolism in adult patients with NVAF 
with one or more risk factors.
3.1.4  Acute Coronary Syndromes
In the phase IIb ATLAS ACS-TIMI 46 (Anti-Xa Therapy 
to Lower cardiovascular events in Addition to aspirin with/
without thienopyridine therapy in Subjects with Acute 
Coronary Syndrome) study, 3491 patients with recent acute 
coronary syndrome (ACS) were randomized to escalating 
total daily doses of rivaroxaban, ranging from 5 mg up to 
20 mg (qd or bid), or placebo, in addition to the standard 
antiplatelet therapy of aspirin or aspirin plus a thienopyri-
dine (eg, clopidogrel) for secondary prevention of cardio-
vascular events [20]. Patients on the rivaroxaban regimens 
had higher rates of hemorrhage than those on placebo, and 
the risk increased in a dose-dependent manner; however, 
no study arm was stopped due to increased hemorrhage. 
A strong trend towards reduction in cardiovascular events 
was observed with rivaroxaban, which reduced the main 
secondary efficacy endpoint of death, myocardial infarc-
tion, or stroke compared with placebo (P = 0.0270). Two 
doses of rivaroxaban were tested in the phase III ATLAS 
ACS 2 TIMI 51 study [21]. The study assigned 15,526 
patients with a recent ACS to receive either 2.5 mg bid or 
5 mg bid of rivaroxaban or placebo for a mean of 13 months 
and up to 31 months. The primary efficacy endpoint was a 
composite of death from cardiovascular causes, myocardial 
infarction, or stroke. The investigators concluded that in 
patients with a recent ACS, rivaroxaban reduced the risk of 
the composite endpoint (8.9 % versus 10.7 %, P = 0.008) 
but increased the risk of major bleeding (2.1 % versus 
0.6 %, P < 0.001) and intracranial hemorrhage (0.6 % 
 versus 0.2 %, P = 0.009) although not the risk of fatal 
 bleeding [21].
Based on the results of the ATLAS ACS 2 TIMI-51 trial 
rivaroxaban 2.5 mg bid was approved by the European 
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Commission based on a positive from the EMA Committee 
for Medicinal Products for Human Use (CHMP) in March 
2013 for secondary prevention of ACS.
3.2  Apixaban
Apixaban is another potent, highly selective, and reversible 
inhibitor of factor Xa and is active against both free enzyme 
and factor Xa bound within the prothrombinase complex 
(Fig. 3.3). The bioavailability of apixaban after oral absorp-
tion is over 50 % [26]. Peak plasma levels of apixaban are 
observed 3 h after administration and plasma concentrations 












between 8 and 15 h, which allows twice-daily administration 
of the drug. The primary elimination route is fecal, with only 
about 25 % eliminated via the kidney. Apixaban has little 
effect on the prothrombin time at therapeutic concentrations, 
but plasma levels can be assessed using a factor Xa inhibition 
assay. The clinical development program of apixaban is sum-
marized in Table 3.4 [27–39].
3.2.1  Venous Thromboembolism Prevention 
in Major Orthopedic Surgery
In a randomized phase II dose-response clinical trial in 1238 
patients undergoing TKR, apixaban 5, 10, or 20 mg/day 
(administered qd or bid) was compared with enoxaparin 
(30 mg bid) and open-label warfarin [27]. Apixaban and 
enoxaparin were started 12–24 h after surgery; the warfarin 
dose was titrated from the evening of the day of surgery. 
After 10–14 days of the treatment, bilateral venography was 
performed and patients were further treated at the attending 
physician’s discretion. The primary endpoint, a composite of 
VTE events plus all-cause mortality at 42-day follow-up, was 
significantly lower in the compound apixaban group (8.6 %) 
than in the enoxaparin (15.6 %, P < 0.02) or warfarin (26.6 %, 
P < 0.001) groups. The primary endpoint rates for apixaban 
2.5 mg bid (9.9 %) and 5.0 mg qd (11.3 %) were lower than 
in the enoxaparin (15.6 %) and warfarin group (26.6 %). The 
incidence of major hemorrhage in apixaban-treated patients 
was low and ranged from 0 (2.5 mg bid) to 3.3 % (20 mg qd), 
with comparable results for once- and twice-daily administra-
tion. No major hemorrhage was observed in the enoxaparin 
and warfarin groups [27].
The clinical utility of apixaban for VTE prevention after 
major joint surgery was investigated in the phase III 
ADVANCE program (Table 3.4). In two multicenter, ran-
domized, double-blind, active-controlled clinical trials 
(ADVANCE-1 and ADVANCE-2), the safety and efficacy of 
oral apixaban (2.5 mg bid) versus enoxaparin (30 mg bid in 
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Table 3.4 Clinical development of apixaban













































ADVANCE-1 and 40 mg qd in ADVANCE-2) for preventing 
DVT and PE after TKR was evaluated in 3195 patients in 
ADVANCE-1 and 3057 patients in ADVANCE-2 (Table 3.5) 
[28, 29]. The duration of treatment was 12 days and the pri-
mary outcome of both studies was defined as a combination 
of asymptomatic and symptomatic DVT, nonfatal PE and 
all-cause mortality. In ADVANCE-1, apixaban did not meet 
the pre-specified statistical criteria for non-inferiority versus 
enoxaparin, but its use was associated with lower rates of 
clinically relevant bleeding and it had a similar adverse-event 
profile [28]. In ADVANCE-2, apixaban 2.5 mg bid, starting 
the morning after TKR, offered a more effective orally 
administered alternative to 40 mg per day enoxaparin (rela-
tive risk 0.62; 95 % CI 0.51–0.74; P < 0.0001), without increased 
bleeding rates (Table 3.5) [29].
Similarly, in the ADVANCE-3 trial, the efficacy and safety 
of 5-week administration of apixaban (2.5 mg bid) in com-
parison with enoxaparin in the prevention of DVT and PE 
was assessed in 5407 patients after THR. Patients were ran-
domized to receive apixaban plus placebo or enoxaparin plus 
placebo for 5 weeks. The primary outcome was again a 
 combination of asymptomatic and symptomatic DVT, nonfa-
Table 3.4 (continued)
Clinical condition Trial Comparator (n)






ADOPT [38] Enoxaparin (6528)
























































































































































































































































































































































































































































































































































































































































































































































































tal PE, and all-cause mortality. The ADVANCE-3 investiga-
tors concluded that, among patients undergoing hip 
replacement, apixaban was associated with lower rates of 
VTE without increased bleeding compared with subcutane-
ous enoxaparin (relative risk with apixaban, 0.36; 95 % CI, 
0.22–0.54; P < 0.001 for both non-inferiority and superiority) 
(Table 3.5) [30].
Apixaban received approval in the EU for the prevention 
of VTE in patients undergoing elective THR or TKR surgery 
in May 2011. In March 2014 apixaban was approved by the 
FDA for the prevention of VTE following hip or knee 
replacement surgery.
3.2.2  Stroke Prevention in Atrial Fibrillation
Two phase III clinical trials assessed apixaban for stroke pre-
vention in patients with AF. In the first, the AVERROES 
study, the effectiveness of oral apixaban (5 mg bid; or 2.5 mg 
in selected patients) was compared with aspirin (81–324 mg 
qd) for 36 months in the prevention of stroke or systemic 
embolism in 5599 patients with permanent or persistent AF 
who had at least one additional risk factor for stroke but 
could not be treated with VKA (Table 3.6) [34]. The data and 
safety monitoring board recommended early termination of 
the study because of a clear benefit in favor of apixaban. 
Apixaban compared with aspirin, reduced the risk of stroke 
or systemic embolism (1.6 % versus 3.7 % per year, respec-
tively, P < 0.001) without significantly increasing the risk of 
major bleeding or intracranial hemorrhage [34].
The second phase III trial, the ARISTOTLE study, investi-
gated whether apixaban (5 mg bid) was as effective as warfarin 
in preventing stroke and systemic embolism in 18,201 patients 
with AF who had at least one additional risk factor for 
stroke [35]. The primary efficacy endpoint was the composite 
outcome of stroke or systemic embolism. In ARISTOTLE, 
apixaban reduced the risk of stroke or  systemic embolism by 
21 % compared with warfarin. The reduction was significant 
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(P < 0.01) and supported the superiority of apixaban over war-
farin for the primary outcome of preventing stroke or systemic 
embolism. Apixaban also reduced all-cause mortality by 11 % 
and major bleeding by 31 % (Table 3.6) [35]. Apixaban has 
become the first new oral anticoagulant superior to warfarin in 
reducing stroke or systemic embolism, all-cause mortality, and 
major bleeding in patients with AF. Apixaban received 
approval by the European Commission for the prevention of 
stroke and systemic embolism in patients with non-valvular 
AF in November 2012 and by the FDA in December 2012.
3.2.3  Thromboprophylaxis in Other Clinical 
Settings
Apixaban is being tested in several additional settings, which 
may expand the use of oral anticoagulation beyond currently 
established indications. The phase II randomized ADVOCATE 
study has been designed to determine the tolerability, effec-
tiveness, and safety of apixaban in prevention of thrombolic 
events in patients with advanced or metastatic cancer on pre-
scribed chemotherapy for more than 90 days [39]. In this 
randomized double-blind study 12-week administration of 
apixaban (5, 10, or 20 mg qd, n = 95 overall) was compared 
with placebo (n = 30). The primary outcome was either major 
bleeding or CRNM bleeding and secondary outcomes 
included VTE and grade III or higher adverse events related 
to the study drug. Although the study appeared to show a 
favorable safety profile for apixaban, it was underpowered to 
draw any reliable conclusions and further phase III evaluation 
of apixaban in this setting would be appropriate [39].
A further phase III randomized trial, ADOPT, compared the 
safety and efficacy of apixaban with enoxaparin in preventing 
DVT and PE in patients hospitalized with congestive heart fail-
ure, acute respiratory failure, infection (without septic shock), 
acute rheumatic disorder, or inflammatory bowel disease [38]. A 
total of 6528 subjects underwent randomization, 4495 of whom 
could be evaluated for the primary efficacy  outcome: 2211 in the 
3.2 Apixaban
46
apixaban group and 2284 in the enoxaparin group. The primary 
outcome was the composite of VTE or VTE-related death, 
whereas secondary outcome measures included all-cause mor-
tality, major hemorrhage, and CRNM hemorrhage. Among the 
patients who could be evaluated, 2.71 % in the apixaban group 
and 3.06 % in the enoxaparin group met the criteria for the 
primary efficacy outcome (relative risk with apixaban, 0.87; 
95 % CI, 0.62–1.23; P = 0.44). Major bleeding occurred in 0.47 % 
of the patients in the apixaban group and in 0.19 % of the 
patients in the enoxaparin group. The investigators therefore 
 concluded that in medically ill patients, an extended course of 
thromboprophylaxis with apixaban was not superior to a shorter 
course with enoxaparin and was associated with significantly 
more major bleeding events than was enoxaparin [38].
Table 3.6 Clinical efficacy and safety of apixaban for stroke preven-
tion in atrial fibrillation
AVERROES trial
Apixaban 
5 mg bid 
(n = 2808)
Aspirin 
81–324 mg qd 
(n = 2791)
Occurrence of stroke 
(ischemic or hemorrhagic) 
or systemic embolism, n/N 
(%/y)
51/2808 (1.6) 113/2791 (3.7)
Major Bleeding, n/N (%/y) 44/2808 (1.4) 39/2791 (1.2)
ARISTOTLE trial
Apixaban 




Occurrence of stroke or 
systemic embolism, n/N 
(%/y)
212/9120 (1.3) 265/9081 (1.6)
Major bleeding, n/N (%/y) 327/9088 (2.1) 462/9052 (3.1)
Data from [34, 35]
bid twice daily, qd once daily
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3.2.4  Treatment of Venous Thrombosis
Investigation of the utility of apixaban for the treatment of 
patients with VTE started with the phase II Botticelli DVT 
dose-ranging clinical trial [31]. In this study 520 patients with 
symptomatic DVT were randomized to receive apixaban 
(5 mg or 10 mg bid or 20 mg qd) or traditional treatment with 
LMWH or fondaparinux followed by VKA. After manage-
ment for 84–91 days, no significant difference was reported 
between the treatments in the rate of occurrence of the pri-
mary outcome, a composite of symptomatic recurrent VTE 
and asymptomatic deterioration of bilateral compression 
ultrasound or perfusion lung scan (4.7 % for apixaban and 
4.2 % in control patients) [31]. The primary outcome rates for 
the tested apixaban doses were 6.0 % for 5 mg bid, 5.6 % for 
10 mg bid, and 2.6 % for 20 mg qd. The principal safety out-
come (a composite of major and CRNM hemorrhage) devel-
oped at a similar rate in the apixaban-treated patients 
(7.3 %) and the control group (7.9 %). The principal safety 
outcome rates for the tested apixaban doses were 8.6 % for 
5 mg bid, 4.5 % for 10 mg bid, and 7.3 % for 20 mg qd.
In the Phase III randomized, multicenter AMPLIFY study 
[32] apixaban was compared with the conventional treatment 
(enoxaparin/warfarin) in 5395 patients with VTE. Patients 
randomized to apixaban received 10 mg bid for 7 days fol-
lowed by 5 mg bid for 6 months. The primary outcome was 
the rate of symptomatic, recurrent VTE and related deaths; 
the principal safety outcomes were major bleeding alone and 
major bleeding plus CRNM bleeding. The results from the 
AMPLIFY study found apixaban to be non-inferior to con-
ventional therapy, with symptomatic recurrent VTE  occurring 
in 2.3 % of patients in the apixaban group and 2.7 % of 
patients who received conventional therapy (relative risk, 
0.84; P < 0.001) (Table 3.7). Rates of VTE or cardiovascular 
(CV)-related death and VTE or all-cause death were lower in 
patients who received apixaban compared with those who 
received standard therapy. Moreover, apixaban resulted in 
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103 (3.8) 215 (8.0)
(continued)
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Additionally, the AMPLIFY-EXT trial assessed the effi-
cacy and safety of apixaban in preventing VTE recurrence or 
death in 2486 patients with clinical diagnosis of DVT or PE 
who had completed 6–12 months of standard treatment for 
DVT or PE or had completed treatment with apixaban or 
enoxaparin and warfarin as participants in the AMPLIFY 
trial [33]. Patients received apixaban (2.5 or 5 mg bid) or pla-
cebo for 12 months. The study found that VTE or related 
death occurred in 8.8 % of patients who received placebo, as 
compared with 1.7 % who received apixaban 2.5 mg (95 % CI 
5.0–9.3) and 1.7 % apixaban 5 mg (95 % CI 4.9–9.1; P < 0.001 
for both). There were fewer significant events of primary 
outcome with the both apixaban 2.5 mg (relative risk 0.33 
[95 % CI 0.22–0.48]) and 5 mg (relative risk 0.36 [95 % CI 
0.25–0.53]) compared with placebo (Table 3.7). Bleeding 
results from the AMPLIFY-Extension study showed that 
both apixaban 2.5 mg and 5 mg doses were associated with 
low bleeding levels that were similar to placebo [33].
Based on the results of the AMPLIFY and AMPLIFY-Ext 
studies in June 2014 apixaban was approved in the EU for the 




2.5 mg bid 
(n = 840)
Apixaban 
5 mg bid 
(n = 813)
Placebo (n = 829)
Symptomatic 
recurrent 
VTE or death 
from any 
cause, n (%)
32 (3.8) 34 (4.2) 96 (11.6)
Major bleeding, 
n (%)
2 (0.2) 1 (0.1) 4 (0.5)
Data from [31–33]
bid twice daily, LMWH low-molecular weight heparin, qd once daily, 
VKA vitamin K antagonist, VTE venous thromboembolism
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approval in August 2014, apixaban 2.5 mg and 5 mg was 
approved by the FDA for the treatment of recurrent DVT 
and PE following initial therapy.
3.2.5  Acute Coronary Syndrome
The phase II APPRAISE-1 clinical trial evaluated the safety 
of apixaban in 1715 patients with recent ACS. Patients were 
randomized to receive apixaban (2.5 mg bid or 10.0 mg qd) 
or placebo for 26 weeks. The primary outcome was the inci-
dence of major or CRNM hemorrhage; the secondary out-
come was a composite of cardiovascular death, nonfatal 
myocardial infarction, severe recurrent ischemia, or ischemic 
stroke. The investigators reported a dose-related increase in 
bleeding compared with placebo (apixaban 2.5 mg bid: HR, 
1.78; 95 % CI 0.91–3.48; P = 0.09; 10 mg qd: HR, 2.45; 95 % CI, 
1.31–4.61; P = 0.005) and a trend toward a reduction in isch-
emic events with the addition of apixaban to antiplatelet 
therapy in patients with recent ACS [36]. Whether apixaban 
could improve outcomes in patients after an ACS was further 
investigated in the phase III trial APPRAISE-2. This trial was 
a randomized, double-blind, placebo-controlled clinical trial 
comparing apixaban, at a dose of 5 mg bid, with placebo, in 
addition to standard antiplatelet therapy, in patients with a 
recent ACS and at least two additional risk factors for recur-
rent ischemic events. The trial was terminated prematurely 
due to an increase in major bleeding events with apixaban in 
the absence of a counterbalancing reduction in recurrent 
ischemic events [37].
3.3  Edoxaban
Edoxaban (Fig. 3.4) is a potent, highly selective factor Xa 
inhibitor with a high affinity for free factor Xa (Ki 0.56 
nM) and for factor Xa bound to the prothrombinase com-
plex (Ki 2.98 nM) [40]. It has predictable and consistent 
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 pharmacokinetics with dose proportional increases in plasma 
concentrations, and a half-life of approximately 10–14 h [10, 
41, 42]. Additionally, edoxaban has a rapid onset of action 
and high oral bioavailability (61.8 %), reaching maximum 
plasma concentrations 1–2 h after administration, and inhibi-
tion of thrombin formation over ~24 h, supporting once-daily 
dosing [10, 12, 43]. Moreover, edoxaban is mainly metabo-
lized via hydrolysis, whereas CYP450 enzymes play an insig-
nificant role.
Around 35 % of the given dose is eliminated via the kid-
neys [44], indicating the importance of the kidneys in the 
excretion of edoxaban. Consequently, studies have evaluated 
edoxaban in patients with renal impairment and suggest that 
in patients with chronic kidney disease, edoxaban exposure is 
increased and a lower dose is appropriate [45].
The pharmacokinetics of edoxaban are not influenced by 
gender, age, ethnicity, or food intake, although small but clini-
cally insignificant changes in pharmacokinetics after a high fat 
meal or in the elderly is observed [10, 46]. Edoxaban has mini-
mal drug interactions, however like all factor Xa inhibitors, 




















fore has potential for interaction with strong P-gp inhibitors. 
As such, a 50 % dose reduction to edoxaban 30 mg is recom-
mended when concomitantly used with the P-gp inhibitors, 
ciclosporin, dronedarone, erythromycin, or ketoconazole. In 
contrast no dose adjustment is necessary with amiodarone, 
quinidine or verapamil [47]. The predicable pharmacokinetic 
and pharmacodynamics profiles of edoxaban allows for its use 
without regular laboratory monitoring [10].
Similar to other factor Xa inhibitors, currently there is no 
antidote for edoxaban. However a recently completed phase I 
study evaluated the effects of PER977 on bleeding following 
administration of edoxaban to healthy subjects (clinicaltrials.
gov identifier NCT01826266) [48]. PER977 was found to be 
effective in restoring baseline hemostasis 10–30 min after 
administration of 100–300 mg PER977, this effect was sustained 
for 24 h [49]. An additional phase II study is underway investi-
gating the re-anticoagulation effect of edoxaban following 
reversal by PER977 (clinicaltrials.gov identifier NCT02207257) 
[50]. This trial also aims to identify a dose regimen of PER977 
that is able to reverse the effects of edoxaban for 21 h.
Edoxaban was approved in Japan for prevention of VTE 
following lower-limb orthopedic surgery and in the US for 
the prevention of stroke and systemic embolic events (SEE) 
in NVAF and for the treatment of PE and DVT and preven-
tion of recurrent VTE [51]. Edoxaban received European 
approval in June 2015 following a positive opinion from the 
CHMP for the use of edoxaban for the prevention of AF 
related stroke and treatment of PE and DVT and prevention 
of recurrent VTE [52]. The clinical development of edoxaban 
can be seen in Table 3.8.
3.3.1  Venous Thromboembolism Prevention 
in Major Orthopedic Surgery
Two phase II dose-finding studies, 011 [54] and J04 [53], 
investigated the use of edoxaban for the prevention of VTE 
after joint replacement. Study J04 was a placebo controlled 
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study that evaluated edoxaban 5, 15, 30, or 60 mg qd for pre-
vention of VTE following TKR in Japanese patients [53]. 
Patients were treated for 11–14 days following surgery. There 
was a significant, dose-dependent reduction in the incidence 
of VTE with edoxaban compared with placebo, with a com-
parable risk of bleeding across all treatment groups with no 
significant differences among edoxaban doses or between 
edoxaban and placebo.
In the double-blind, active-controlled, multicenter 011 
study, 903 patients were randomized to receive oral edoxaban 
(15, 30, 60, or 90 mg od) or subcutaneous dalteparin qd 
Table 3.8 Clinical development program for edoxaban




Study J04 [53] Placebo (523)
Study 011 [54] Dalteparin (774)
Phase III
STARS E-III [55] Enoxaparin (716)
STARS J-IV [56] Enoxaparin (92)
STARS J-V [57] Enoxaparin (610)
Stroke prevention in 
atrial fibrillation
Phase II





Prevention of VTE Phase III





 (initial dose 2500 IU, subsequent doses 5000 IU) [54]. Both 
medications were started 6–8 h after surgery and adminis-
tered for 7–10 days. Data from 776 participants were included 
into the primary efficacy analysis. The primary efficacy end-
point of total VTE was significantly lower in subjects treated 
with edoxaban (28.2 %, 21.2 %, 15.2 %, and 10.6 % for 
edoxaban 15, 30, 60, and 90 mg, respectively) than in those 
receiving dalteparin (43.8 %, P < 0.005) (Table 3.9).
The open-label STARS J-IV [56] trial investigated the 
safety and efficacy of edoxaban in preventing VTE after 
major joint surgery in 92 Japanese patients undergoing hip 
fracture surgery. Patients were randomized to either edoxa-
ban 30 mg qd (6–24 h post-surgery) or enoxaparin 2000 IU 
bid (24–36 h after surgery). The primary endpoints were 
bleeding events and secondary events included thromboem-
bolic events and adverse events. STARS J-IV found that 
treatment with edoxaban was as safe and efficacious as 
enoxaparin treatment, and major or CRNM bleeding 
occurred less often in the edoxaban group compared with the 
enoxaparin group (3.4 % and 6.9 % respectively). However, 
thromboembolic events occurred more often in the edoxaban 
group (6.5 % vs 3.7 %) (Table 3.9).
Two pivotal, randomized, double-blind, multicenter, phase 
III trials compared edoxaban 30 mg qd to enoxaparin in knee 
surgery, STARS E-III [55], and hip surgery, STARS J-V [57]. 
In both STARS E-III and STARS J-V edoxaban 30 mg qd 
was superior to enoxaparin in the preventions of VTE, with 
comparable rates of bleeding [55, 57]. Supported by the data 
from these phase III studies edoxaban was approved in Japan 
in April 2011 for the prevention of VTE following lower-limb 
orthopedic surgery.
A post-marketing vigilance report [63] recorded all spon-
taneously reported adverse drug reactions (ADR) that 
occurred following the launch of edoxaban in Japan, from 
July 2011 to January 2012. During this time approximately 
20,000 patients had been treated with edoxaban. A total of 67 
ADR were reported in 57 patients, the majority of ADR were 
bleeding events, 15 of which were serious. Most ADR 
occurred in the first week of treatment and none were fatal. 
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Table 3.9 Clinical efficacy and safety of edoxaban in prevention of 
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The post-marketing analysis found that in the real-life setting 
the safety profile of edoxaban was consistent with that found 
in clinical trials and no unforeseen safety signals were 
observed.
3.3.2  Stroke Prevention in Atrial Fibrillation
In a parallel-group, active controlled phase II study the safety 
of four fixed-dose regimens of edoxaban were compared with 
warfarin in 1146 patients with NVAF. Patients were random-
Table 3.9 (continued)
STARS J-IV
Edoxaban 30 mg qd 
(n = 59)
Enoxaparin 




2/59 (3.4) 2/29 (6.9)
Thromboembolic 
events, n/N (%)
3/46 (6.5) 1/27 (3.7)
STARS J-V
Edoxaban 30 mg qd 
(n = 303)
Enoxaparin 20 mg 




DVT, and PE, 
n/N (%)
6/255 (2.4) 17/248 (6.9)
Major and CRNM 
bleeding, n/N (%)
8/303 (2.6) 11/301 (3.7)
Data from [53–57]
bid twice daily, CRNM clinically relevant non-major, DVT deep vein 
thrombosis, PE pulmonary embolism, qd once daily, VTE venous 
thromboembolism
Chapter 3. Factor Xa Inhibitors
57
ized to edoxaban 30 mg od, 60 mg od, 30 mg bid, 60 mg bid, 
or warfarin (INR 2.0–3.0) [58]. A significantly higher inci-
dence of major and/or CRNM bleeding was seen in the twice- 
daily edoxaban regimen (60 mg bid, 10.6 %, P = 0.002; 30 mg 
bid, 7.8 %, P = 0.029) than warfarin (3.2 %), however there 
were no significant differences between the warfarin and 
once-daily regimens. For the same total daily dose of edoxa-
ban, 60 mg, the 30 mg bid dose was associated with a trend 
towards an increase in major bleeding plus CRNM bleeding 
compared with 60 mg qd (P = 0.08). This study concluded that 
treatment with edoxaban 30 or 60 mg qd was safe and well 
tolerated.
A pooled pharmacokinetic analysis [64] was performed on 
data from 15 phase I and II studies which aimed to character-
ize edoxaban population pharmacokinetics. Using an 
exposure- response analysis (in which Cmin was the best pre-
dictor of bleed probability), a 50 % dose reduction in selected 
patients was recommended, especially in patients with renal 
impairment, concomitant use of P-gp inhibitors, and body 
weight ≤60 kg. Consequently, two doses of edoxaban (30 mg 
and 60 mg od) were selected for investigation in the phase III 
ENGAGE AF-TIMI 48 trial.
The ENGAGE AF-TIMI 48 study [59] investigated the 
safety and efficacy of two doses of edoxaban compared with 
warfarin. A total 21,105 patients with a history of AF were 
enrolled into the study making this the largest study of a 
NOAC in patients with AF to date. Patients were randomized 
to edoxaban 60 mg qd (n = 7012), edoxaban 30 mg qd 
(n = 7002) or warfarin (n = 7012; median time in therapeutic 
range, 68.4 %). In the edoxaban group, patients with moderate 
renal impairment (creatinine clearance [CrCl] 30–50 mL/
min), weight ≤60 kg or who were receiving select P-gp inhibi-
tors had a 50 % dose reduction. Median follow-up duration 
was 2.8 years. The primary efficacy objective was the non- 
inferiority of edoxaban compared with warfarin in the preven-
tion of stroke and SEE, key secondary outcomes included a 
composite of stroke, SEE or death from CV causes, major 
adverse cardiac events (MACE), and stroke, SEE or death [59]. 
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The primary safety outcome was major bleeding during treat-
ment. The primary efficacy endpoint occurred in 232 patients 
treated with warfarin (1.50 %/y), 182 patients treated with 
edoxaban 60 mg qd (1.18 %/y; HR vs warfarin 0.79, 95 % CI 
0.63–0.99; P < 0.001 for non-inferiority), and 253 patients treated 
with edoxaban 30 mg qd (1.61 %/y; HR vs warfarin 1.07. 95 % 
CI 0.87–1.31; P = 0.005 for non- inferiority). Additionally, 
ENGAGE AF-TIMI 48 met the pre-specified criteria for non-
inferiority and both doses were compared with warfarin in a 
test for superiority. For patients treated with warfarin the annu-
alized rate of the primary endpoint was 1.80 % compared with 
1.57 % in the edoxaban 60 mg qd group (HR 0.87, CI 0.73–1.08; 
P = 0.08), and 2.04 % in the edoxaban 30 mg qd group (HR 1.13, 
CI 0.96–1.34; P = 0.10) (Fig. 3.5) [60].
The primary safety endpoint of major bleeding occurred in 




















Hazard ratio and 97.5 % confidence intervals
High-dose edoxaban vs. warfarin, 0.87 (0.73 – 1.04); P=0.08


















Figure 3.5 Kaplan-Meier curve for stroke of systemic embolic 
events in ENGAGE AF-TIMI 48 (Reproduced with permission 
from Giugliano et al. [60])
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418 patients in the edoxaban 60 mg qd group (2.75 %/y; HR 
0.80; 95 % CI, 0.71–0.91; P < 0.001), and 254 patients in the 
edoxaban 30 mg qd group (1.61 %/y; HR, 0.47; 95 % CI, 
0.41–0.55; P < 0.001) (Fig. 3.6) [60]. The rates of all three pre- 
specified secondary outcomes were significantly lower with 
edoxaban 60 mg than with warfarin.
Based on the findings from ENGAGE AF-TIMI 48, edox-
aban 60 mg was approved by the FDA in January 2015 for the 
prevention of stroke and SEE in NVAF. According to the 
label given by the FDA edoxaban 60 mg dose should be 
reduced to 30 mg in patients with a CrCl 15–30 mL/min and 
should not be used in patients with CrCl >95 mL/min due to 
increased risk of ischemic stroke compared with warfarin. In 
ENGAGE AF-TIMI 48, 77 % of patients had a CrCl <95 mL/
min [52]. Additionally, edoxaban received European approval 




















Hazard ratio and 97.5 % confidence intervals
High-dose edoxaban vs. warfarin, 0.80 (0.71– 0.91); P<0.001




















Figure 3.6 Kaplan-Meier curve for major bleeding events in 
ENGAGE AF-TIMI 48 (Reproduced with permission from 
Giugliano et al. [60])
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edoxaban in Europe in patients with NVAF, which did not 
include a limitation according to renal function [52]. Edoxaban 
has also been approved in Japan and Switzerland for preven-
tion of ischemic stroke and systemic embolism in patients 
with AF.
3.3.3  Treatment of Venous Thromboembolism
The phase III, event-driven, randomized, double-blind, 
double- dummy, parallel-group, multinational study 
 Hokusai- VTE [61, 62] investigated the safety and efficacy of 
edoxaban in prevention of VTE. The design of Hokusai-VTE 
aimed to broaden the applicability of edoxaban use in VTE 
treatment to real world practice, and encourage enrolment of 
a broad type of patients, including those with extensive dis-
ease [61]. Hokusai-VTE allowed for variable treatment dura-
tion from 3 to 12 months, regardless of treatment duration all 
patients were observed for 12 months [61].
A total of 8292 patients were randomized to receive open- 
label heparin (for ≥5 days) followed by either edoxaban 60 mg 
qd (started after discontinuation of heparin) or warfarin 
(started concurrently with heparin and until INR 2.0–3.0). A 
50 % dose adjustment occurred in the edoxaban group at 
randomization and any point during the study in patients with 
moderate renal impairment (CrCl 30–50 mL/min), weight 
≤60 kg or who were receiving select P-gp inhibitors. Hokusai-
VTE was unique in that dose adjustment not only occurred at 
randomization but could occur at any point during the study 
as necessary. Additionally, the flexible treatment duration is 
unique to Hokusai-VTE, which is unusual in clinical trials but 
is more in line with clinical practice. The primary efficacy end-
point was symptomatic recurrent VTE during the 12 month 
study period and the objective of the study was to determine 
the non-inferiority of heparin follow by edoxaban compared 
with heparin followed by warfarin. The secondary endpoints 
included a composite of symptomatic recurrent DVT, non-
fatal symptomatic recurrent PE and all-cause  mortality, and a 
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composite clinical outcome of symptomatic recurrent DVT, 
non-fatal symptomatic recurrent PE, and CV mortality. The 
primary safety endpoint was major or CRNM bleeding, sec-
ondary endpoints included all deaths, major adverse cardio-
vascular events, liver enzyme and bilirubin abnormalities. 
Over the 12 month study period edoxaban was found to be 
non-inferior to warfarin for the primary outcomes; symptom-
atic recurrent VTE occurred in 3.2 % of patients in the edoxa-
ban group and 3.5 % of patients in the warfarin group (HR 
0.89; 95 % CI, 0.70–1.13; P < 0.001 for non-inferiority) (Fig. 3.7).
Additionally, Hokusai-VTE analyzed events that occurred 
on-treatment. Symptomatic recurrent VTE occurred in 1.6 % 
of the edoxaban group and 1.9 % of the warfarin group (HR, 
0.82; 95 % CI, 0.60–1.14; P < 0.001 for non-inferiority). In a 
pre-specified analysis of patients that required dose adjust-
ment edoxaban was also found to be non-inferior to warfarin, 
with events occurring in 3.0 % and 4.2 %, respectively (HR, 
0.73; 05 % CI, 0.42–1.26). In the subgroup of patients with PE 
and evidence of right ventricular dysfunction (N-terminal- 
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Figure 3.7 Kaplan-Meier cumulative event rates for the symptom-
atic recurrent VTE in Hokusai-VTE (Reproduced with permission 
from The Hokusai-VTE Investigators [62])
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recurrent VTE occurred in 3.3 % of patients (15/454) in the 
edoxaban group and in 6.2 % of patients (30/484) in the war-
farin group (HR, 0.52; 95 % CI, 0.28–0.98). Similar results 
were observed among patients with right ventricular dysfunc-
tion as assessed by means of computed tomography (HR, 0.42; 
95 % CI, 0.15–1.20). During the 12 month study period the 
primary safety outcome occurred in 8.5 % of the edoxaban 
group and 10.3 % of the warfarin group (HR, 0.81; 95 % CI, 
0.71–0.94; P = 0.004 for superiority) demonstrating that edoxa-
ban caused significantly less bleeding than warfarin (Fig. 3.8).
In the pre-specified analyses of the dose adjusted edoxa-
ban patients first major or CRNM bleeding occurred in 7.9 % 
of edoxaban patients and 12.8 % of warfarin patents (HR, 
0.62; 95 % CI, 0.44–0.86).
In January 2015, based on the results from Hokusai-VTE, 
edoxaban 60 mg was approved in the US for the treatment of 
DVT and PE following 5–10 days parenteral heparin. In 
patients with CrCl 30–50 mL/min, body weight ≤60 kg and 
patients receiving concomitant P-gp inhibitors edoxaban 
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Figure 3.8 Kaplan-Meier curve of major of clinically relevant non- 
major bleeding events in Hokusai-VTE (Reproduced with permis-
sion from The Hokusai-VTE investigators [62])
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on data from Hokusai-VTE edoxaban was recommended by 
the CHMP for the treatment of DVT and PE and prevention 
of recurrent PE and DVT in adults [52]. Edoxaban has also 
been approved in Japan and Switzerland for VTE treatment 
and secondary prevention.
3.4  Emerging Factor Xa Inhibitors
Currently, the factor Xa inhibitor betrixaban (PRT-054021) is 
in phase III clinical development for the prevention of 
thromboembolism and the partial factor IXa inhibitor 
TTP889 is in phase II development for the prevention of 
VTE reflecting interest in the high clinical potential of this 
pharmaceutical group (Table 3.10) [65–67]. Enrollment has 
begun for a phase I study to assess the safety, tolerability, 
pharmacokinetics and pharmacodynamics of the direct factor 
Xa inhibitor GCC-4401C compared with placebo and rivar-
oxaban (clinicaltrials.gov identifier NCT01954238) [68].
3.4.1  Betrixaban
Betrixaban (PRT-054021) specifically and reversibly inhibits 
factor Xa with a Ki of 0.117 nmol/L. It has a bioavailability of 
47 %, a half-life of 19 h, and is excreted almost unchanged in 
bile. Betrixaban has demonstrated antithrombotic activity in 
animal models and in human blood. It is well tolerated in 
healthy individuals across a wide range of doses. Betrixaban 
has been investigated in phase II trials for VTE prevention in 
patients after major joint surgery (EXPERT) [65] and for 
stroke prevention in patients with AF (EXPLORE-Xa) [66]. 
Currently a phase III double-blind trial of betrixaban is 
recruiting patients, with the aim of enrolling ~6850 patients, 
to evaluate the extended treatment (35–42 days) of oral 
betrixaban in hospitalized patients compared with standard 
treatment of enoxaparin (clinicaltrials.gov identifier 
NCT01583218) [69]. Primary efficacy endpoint is a composite 
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of asymmetrical proximal DVT, symptomatic DVT, non-fatal 
PE, or VTE-related death through day 35, primary safety 
outcome is major bleeding [70].
3.4.2  TTP889
TTP889 is a small-molecule, orally available selective factor 
IXa antagonist with a dose-dependent inhibition of factor 
IXa ≈ 90 % [67] and a half-life between 21 and 25 h [71]. In an 
Table 3.10 Clinical development of emerging factor Xa inhibitors
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exploratory study of the antithrombotic potential of TTP889, 
260 patients, who had hip fracture repair and who and had 
received LMWH or unfractionated heparin for thrombopro-
phylaxis 5–9 days after surgery, were randomized to receive 
TTP889 300 mg or placebo. No significant differences in the 
number of total VTE events were observed, and no major 
bleeding occurred [67] Further studies are warranted [67, 71].
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